GlassScriptPhysician profile
Kindrell Tucker
NPI 1245586296
$7,485.80
in general payments reported to CMS, 2019-2025
35 companies · $546 in 2025
The $546 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,837 · 2020: $627 · 2021: $958 · 2022: $922 · 2023: $1,441 · 2024: $1,155 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,123 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,122.75 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,466.99 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,097.44 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $919.97 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $799.20 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $528.36 | 2022-2025 | |
| Glaxosmithkline, LLC. | $299.38 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $288.48 | 2021-2025 | Ubrelvy, Qulipta |
| Kci USA, INC. | $283.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $208.04 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $159.38 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $149.38 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $140.32 | 2019-2023 | |
| Ironshore Pharmaceuticals INC. | $125.69 | 2019 | |
| Idorsia Pharmaceuticals US INC | $122.18 | 2022-2025 | Quviviq, Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.55 | 2023-2025 | Jardiance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $106.63 | 2021-2024 | Freestyle Libre 3 |
| Amgen INC. | $85.28 | 2019-2024 | Repatha, Otezla |
| Dexcom, INC. | $84.04 | 2022-2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $76.23 | 2023-2024 | Yupelri |
| Alnylam Pharmaceuticals INC. | $55.37 | 2022 | |
| Medtronic, INC. | $50.00 | 2024 | Abre |
| Allergan, INC. | $40.15 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $36.07 | 2022-2024 | Camzyos |
| Exact Sciences Corporation | $33.52 | 2023 | Cologuard Collection Kit |
| Almatica Pharma LLC | $31.43 | 2021 | |
| Astellas Pharma US INC | $30.69 | 2019 | |
| Shire North American Group INC | $22.43 | 2019 | |
| Paratek Pharmaceuticals, INC. | $21.97 | 2023 | Nuzyra |
| Sun Pharmaceutical Industries INC. | $20.33 | 2022 | |
| Shield Therapeutics INC | $19.86 | 2023 | |
| Xeris Pharmaceuticals, INC. | $15.06 | 2025 | Gvoke Hypopen |
| Currax Pharmaceuticals LLC | $14.52 | 2023 | Onzetra Xsail, Contrave |
| Eisai INC. | $14.06 | 2021 | |
| Amarin Pharma, INC. | $12.94 | 2019 | |
| Cmp Pharma, INC. | $12.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kindrell Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.